Tao Fu
Net Worth
Last updated:
What is Tao Fu net worth?
The estimated net worth of Mr. Tao Fu is at least $17,548,918 as of 28 Oct 2021. He owns shares worth $3,037,214 as insider, has earned $11,912,624 from insider trading and has received compensation worth at least $2,599,080 in Zai Lab Limited.
What is the salary of Tao Fu?
Mr. Tao Fu salary is $649,770 per year as Chief Strategy Officer in Zai Lab Limited.
How old is Tao Fu?
Mr. Tao Fu is 53 years old, born in 1972.
What stocks does Tao Fu currently own?
As insider, Mr. Tao Fu owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Zai Lab Limited (ZLAB) | Chief Strategy Officer | 85,435 | $35.55 | $3,037,214 |
What does Zai Lab Limited do?
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Tao Fu insider trading
Zai Lab Limited
Mr. Tao Fu has made 13 insider trades in 2021, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of ZLAB stock worth $1,048,100 on 28 Oct 2021.
The largest trade he's ever made was exercising 20,000 units of ZLAB stock on 26 Mar 2021. As of 28 Oct 2021 he still owns at least 85,435 units of ZLAB stock.
Zai Lab Limited key executives
Zai Lab Limited executives and other stock owners filed with the SEC:
- Dr. Alan Bart Sandler M.D. (68) Pres & Head of Global Devel. in Oncology
- Dr. Ying Du (59) Founder, Chairperson & Chief Executive Officer
- Mr. Frazor Titus Edmondson III (59) Chief Legal Officer & Corporation Sec.
- Mr. Ki Chul Cho (47) Chief Financial Officer
- Mr. Tao Fu (53) Chief Strategy Officer